

Supporting Information

Effective Co-delivery of Nutlin-3a and p53 genes via Core-shell Microparticles for Disruption of MDM2-p53 Interaction and Reactivation of p53 in Hepatocellular Carcinoma

*Pooya Davoodi^a, Madapusi P. Srinivasan^{a,b} and Chi-Hwa Wang^{*a}*

*^a Department of Chemical and Biomolecular Engineering, National University of Singapore, 4
Engineering Drive 4, Singapore 117585.*

*^b Civil, Environmental and Chemical Engineering, RMIT University, GPO Box 2476, Melbourne
VIC 3001 Australia.*

**Corresponding author: Tel.: +65-65165079; Fax: +65-67791936, E-mail address:
chewch@nus.edu.sg*

Table S1. Characterization of β -CD-g-CS: degree of substitution

| Sample | β -CD:CS | Degree of substitution (%) |
|------------------------|----------------|----------------------------|
| β -CD-g-CS (1:1) | 0.87 | 4.31 |
| β -CD-g-CS (2:1) | 2.01 | 6.48 |
| β -CD-g-CS (3:1) | 3.02 | 6.99 |
| β -CD-g-CS (6:1) | 5.95 | 8.28 |

Table S2. Drug loading content (DLC) and encapsulation efficiency (EE) of nutlin-3a and p53-pDNA NPs loaded microparticles.

| | Core compartment | | Shell compartment* |
|------|------------------|------------|--------------------|
| | DLC | EE | EE |
| MPs1 | 3.36±0.29 | 83.95±7.25 | - |
| MPs2 | - | - | 51.64±6.39 |
| MPs3 | 2.77±0.23 | 69.22±5.81 | 49.21±4.94 |

* Theoretical loading: 150 µg of pDNA.




Figure S1. Cell viability of β -CD-g-CSs at different β -CD:CS ratios in (a) HepG2 (liver), (b) Hela (ovarian), and (c) C6 glioma (brain) cell lines. PEI-25k and pure CS were considered as controls. The cell viability was determined using MTS assay. Data represent mean \pm standard deviation of at least n = 4.




Figure S2. Gel retardation assay of pDNA/ β -CD-g-CS NPs (β -CD:CS 3:1). (a) The binding efficiency of β -CD-g-CS with pDNA. Lane 1 contains 1 kb DNA ladder. Lane 2 contains 1.0 μ g of naked DNA. Lanes 3 to 7 contained pDNA-NPs (2.0 μ g) at N/P ratios of 4, 5, 6, 7, and 8, respectively. (b) The effect of β -CD-g-CS on integrity of pDNA by digesting the nanoparticles with 20 μ l lysozyme (100 U/ml) and 80 μ l chitosanase (0.25 U/ml) in 50 mM of acetate buffer (pH=5.5). Lane 1 to 5 contained pDNA-NPs (2.0 μ g) at N/P ratios of 4, 5, 6, 7 and 8, respectively. Lane 6 contains 1.0 μ g of naked DNA. Lane 7 contains 1 kb DNA ladder. All samples were electrophorezed in 1 \times TAE on a 1% agarose gel, stained with 1 \times SYBR[®] Gold Nucleic Acid Gel Stain solution, and visualized under an ultraviolet transilluminator and imaged using gel-doc system (G: BOX, Syngene).




Figure S3. Measurement of cell transfection efficiency. Cells were treated by EGFP plasmid DNA, EGFP-pDNA-CS NPs, EGFP-pDNA- β -CD-g-CS NPs, and EGFP-pDNA- β -CD-g-CS NPs/microparticles encapsulated nanoparticles for 6 h. For microparticle formulation, the cells were incubated with particles for 2 days. Data represent mean \pm standard deviation of $n = 3$.




Figure S4. Cell viability results at different concentrations of nutlin-3a, where HepG2 cells were treated for 24 h and 48 h. Data represent mean \pm standard deviation of n=4.




Figure S5. (a) Induction of intracellular ROS in non-apoptotic HepG2 cells. Temporal measurement of ROS levels following free-drugs exposure in HepG2 cells. The cells were

exposed to serially diluted nutlin-3a in the presence and absence of N-Acetyl-L-cysteine (NAC, ROS scavenger, Sigma-Aldrich). The ROS levels were measured after 4 h using H₂DCFDA fluorescent probes. ROS level of non-treated cells at each time-point was considered as negative control. (b) Confocal images depict the increase of intracellular ROS after 4 h of exposure to nutlin-3a solutions. Cell were stained with H₂DCFDA (ROS fluorescent probe: green light) and cell-permeant nuclear counterstain (Hoechst 33342: blue light). Data represent mean \pm standard deviation of n=4. Statistical significance: * $p < 0.05$. Scale bar= 25 μ m.